Pfizer's (PFE) INLYTA Phase 3 Misses Primary Endpoint in Advanced RCC
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE) announced that a Phase 3 study of INLYTA (axitinib) did not meet its primary endpoint of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
